{"protocolSection": {"identificationModule": {"nctId": "NCT02217878", "orgStudyIdInfo": {"id": "CMUMK202"}, "organization": {"fullName": "Collegium Medicum w Bydgoszczy", "class": "OTHER"}, "briefTitle": "Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction", "officialTitle": "A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction.", "acronym": "IMPRESSION"}, "statusModule": {"statusVerifiedDate": "2017-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-08"}, "primaryCompletionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-08-14", "studyFirstSubmitQcDate": "2014-08-14", "studyFirstPostDateStruct": {"date": "2014-08-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-02-04", "resultsFirstSubmitQcDate": "2016-02-04", "resultsFirstPostDateStruct": {"date": "2016-03-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-08-12", "lastUpdatePostDateStruct": {"date": "2017-09-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Jacek Kubica", "investigatorTitle": "Prof. dr hab.", "investigatorAffiliation": "Collegium Medicum w Bydgoszczy"}, "leadSponsor": {"name": "Collegium Medicum w Bydgoszczy", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the IMPRESSION study is to determine whether intravenous administration of morphine prior to ticagrelor administration in ST-segment elevation myocardial infarction (STEMI) patients and in non-ST-segment elevation myocardial infarction (NSTEMI) patients alters the plasma concentrations of ticagrelor and its active metabolite and whether it is associated with any negative impact on the antiplatelet effect of ticagrelor.", "detailedDescription": "The European Society of Cardiology and American Heart Association guidelines recommend use of morphine as a treatment of choice for pain relief in STEMI patients. However, this recommendation, although strong, is only based on expert consensus (class of recommendation I, level of evidence C). Morphine, apart from its analgesic effects, also alleviates the work of breathing and reduces anxiety. On the other hand, despite its favorable analgesic and sedative actions, morphine also exerts adverse effects, which include hypotension, bradycardia, respiratory depression, vomiting and reduction of gastrointestinal motility. Some of the previously listed morphine's side effects could affect the intestinal absorption and thus pharmacokinetics and pharmacodynamics of orally administered drugs which are concomitantly used with morphine. At present, no pharmacokinetic and pharmacodynamic data regarding the concurrent use of morphine and P2Y12 blockers in the STEMI or NSTEMI setting are available. Therefore, evidence-based verification of morphine's influence on pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) could provide a valuable insight in the knowledge regarding modern acute myocardial infarction management.\n\nPredefined subanalysis: aimed to investigate which one of platelet reactivity assessment methods utilized in the study (VASP assay, MEA, LTA, VerifyNow) best reflects concentration of ticagrelor and its active metabolite (AR-C124910XX).\n\nSince there is no reference study examining pharmacokinetics of ticagrelor in STEMI or NSTEMI patients, we decided to perform an internal pilot study of approximately 30 patients (15 patients for each arm) for estimating the final sample size."}, "conditionsModule": {"conditions": ["ST-segment Elevation Myocardial Infarction", "Non-ST-segment Elevation Myocardial Infarction", "VA Drug Interactions"], "keywords": ["ST-segment elevation myocardial infarction", "non-ST-segment elevation myocardial infarction", "ticagrelor", "morphine", "pharmacokinetics", "pharmacodynamics", "drug interactions", "VASP assay", "Multiple Electrode Aggregometry", "VerifyNow"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 74, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Morphine", "type": "ACTIVE_COMPARATOR", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor", "interventionNames": ["Drug: Morphine", "Drug: Ticagrelor"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor", "interventionNames": ["Drug: Placebo", "Drug: Ticagrelor"]}], "interventions": [{"type": "DRUG", "name": "Morphine", "description": "IV bolus injection", "armGroupLabels": ["Morphine"], "otherNames": ["Morphine sulfate"]}, {"type": "DRUG", "name": "Placebo", "description": "IV bolus injection", "armGroupLabels": ["Placebo"], "otherNames": ["Sodium chloride 0,9%"]}, {"type": "DRUG", "name": "Ticagrelor", "description": "180 mg loading dose", "armGroupLabels": ["Morphine", "Placebo"], "otherNames": ["Brilique"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)", "description": "Exposure to ticagrelor during the first 12 hours after ticagrelor loading dose", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose"}], "secondaryOutcomes": [{"measure": "Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-12h)", "description": "Exposure to ticagrelor metabolite during the first 12 hours after ticagrelor loading dose", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose"}, {"measure": "Maximum Concentration of Ticagrelor", "description": "Maximum concentration (Cmax) of ticagrelor", "timeFrame": "12 hours"}, {"measure": "Maximum Concentration of AR-C124910XX", "description": "Maximum concentration (Cmax) of AR-C124910XX", "timeFrame": "12 hours"}, {"measure": "Time to Maximum Concentration for Ticagrelor", "description": "Time to maximum concentration (Tmax) for ticagrelor", "timeFrame": "12 hours"}, {"measure": "Time to Maximum Concentration for AR-C124910XX", "description": "Time to maximum concentration (Tmax) for AR-C124910XX", "timeFrame": "12 hours"}, {"measure": "Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-6h)", "description": "Exposure to ticagrelor during the first 6 hours after ticagrelor loading dose", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose"}, {"measure": "Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-6)", "description": "Exposure to ticagrelor metabolite during the first 6 hours after ticagrelor loading dose", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "prior to the initial ticagrelor dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "30 minutes post ticagrelor dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "1 hour post ticagrelor dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "2 hours post ticagrelor dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "3 hours post ticagrelor dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "4 hours post ticagrelor dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "6 hours post ticagrelor dose"}, {"measure": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "timeFrame": "12 hours post ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "prior to the initial ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "30 minutes post ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "1 hour post ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "2 hours post ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "3 hours post ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "4 hours post ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "6 hours post ticagrelor dose"}, {"measure": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "timeFrame": "12 hours post ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "prior to the initial ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "30 minutes post ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "1 hour post ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "2 hours post ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "3 hours post ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "4 hours post ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "6 hours post ticagrelor dose"}, {"measure": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "timeFrame": "12 hours post ticagrelor dose"}, {"measure": "Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VASP", "description": "Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VASP", "timeFrame": "2 hours"}, {"measure": "Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With MEA", "description": "Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With MEA", "timeFrame": "2 hours"}, {"measure": "Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VerifyNow", "description": "Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VerifyNow", "timeFrame": "2 hours"}, {"measure": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VASP", "description": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VASP", "timeFrame": "12 hours"}, {"measure": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With MEA", "description": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With MEA", "timeFrame": "12 hours"}, {"measure": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VerifyNow", "description": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VerifyNow", "timeFrame": "12 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* provision of informed consent prior to any study specific procedures\n* diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment elevation myocardial infarction\n* male or non-pregnant female, aged 18-80 years old\n* provision of informed consent for angiography and PCI\n\nExclusion Criteria:\n\n* chest pain described by the patient as unbearable or patient's request for analgesics\n* prior morphine administration during the current STEMI or NSTEMI\n* treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment\n* hypersensitivity to ticagrelor\n* current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin\n* active bleeding\n* history of intracranial hemorrhage\n* recent gastrointestinal bleeding (within 30 days)\n* history of coagulation disorders\n* platelet count less than \\<100 x10\\^3/mcl\n* hemoglobin concentration less than 10.0 g/dl\n* history of moderate or severe hepatic impairment\n* history of major surgery or severe trauma (within 3 months)\n* patients considered by the investigator to be at risk of bradycardic events\n* second or third degree atrioventricular block during screening for eligibility\n* history of asthma or severe chronic obstructive pulmonary disease\n* patient required dialysis\n* manifest infection or inflammatory state\n* Killip class III or IV during screening for eligibility\n* respiratory failure\n* history of severe chronic heart failure (NYHA class III or IV)\n* concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment\n* body weight below 50 kg", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Prof. Jacek Kubica, MD, PhD", "affiliation": "Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Miko\u0142aja Kopernika w Toruniu", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Cardiology Department, Dr. A. Jurasz University Hospital", "city": "Bydgoszcz", "state": "Kujawsko-pomorskie", "zip": "85-094", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}]}, "referencesModule": {"references": [{"pmid": "26491112", "type": "DERIVED", "citation": "Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D, Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016 Jan 14;37(3):245-52. doi: 10.1093/eurheartj/ehv547. Epub 2015 Oct 21."}, {"pmid": "25925591", "type": "DERIVED", "citation": "Kubica J, Adamski P, Ostrowska M, Kozinski M, Obonska K, Laskowska E, Obonska E, Grzesk G, Winiarski P, Paciorek P. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2015 Apr 29;16:198. doi: 10.1186/s13063-015-0724-z."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "FG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "37"}, {"groupId": "FG001", "numSubjects": "37"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "required morphine due to chest pain", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "initial diagnosis of STEMI not confirmed", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "BG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "70"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.7", "spread": "10.5"}, {"groupId": "BG001", "value": "62.5", "spread": "10.5"}, {"groupId": "BG002", "value": "61.5", "spread": "10.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "19"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "51"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.6", "spread": "4.3"}, {"groupId": "BG001", "value": "27.4", "spread": "4.0"}, {"groupId": "BG002", "value": "27.5", "spread": "4.2"}]}]}]}, {"title": "STEMI", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "45"}]}]}]}, {"title": "GP IIb/IIIa administration", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "16"}]}]}]}, {"title": "Hypertension", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "36"}]}]}]}, {"title": "Diabetes mellitus", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Dyslipidaemia", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "61"}]}]}]}, {"title": "Current smoker", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Prior AMI", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Prior PCI", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Prior CABG", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Prior non-severe heart failure", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Prior non-haemorrhagic stroke", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Peripheral arterial disease", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Chronic renal disease", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Chronic obstructive pulmonary disease", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Gout", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)", "description": "Exposure to ticagrelor during the first 12 hours after ticagrelor loading dose", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6307", "spread": "4359"}, {"groupId": "OG001", "value": "9791", "spread": "5136"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-12h)", "description": "Exposure to ticagrelor metabolite during the first 12 hours after ticagrelor loading dose", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h, 12h post dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1503", "spread": "1138"}, {"groupId": "OG001", "value": "2388", "spread": "1555"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Concentration of Ticagrelor", "description": "Maximum concentration (Cmax) of ticagrelor", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1156", "spread": "771"}, {"groupId": "OG001", "value": "1683", "spread": "847"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Concentration of AR-C124910XX", "description": "Maximum concentration (Cmax) of AR-C124910XX", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ng/mL", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1085", "lowerLimit": "508", "upperLimit": "1709"}, {"groupId": "OG001", "value": "1043", "lowerLimit": "792", "upperLimit": "1572"}]}]}]}, {"type": "SECONDARY", "title": "Time to Maximum Concentration for Ticagrelor", "description": "Time to maximum concentration (Tmax) for ticagrelor", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4", "lowerLimit": "3", "upperLimit": "12"}, {"groupId": "OG001", "value": "2", "lowerLimit": "2", "upperLimit": "4"}]}]}]}, {"type": "SECONDARY", "title": "Time to Maximum Concentration for AR-C124910XX", "description": "Time to maximum concentration (Tmax) for AR-C124910XX", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4", "lowerLimit": "3", "upperLimit": "12"}, {"groupId": "OG001", "value": "4", "lowerLimit": "3", "upperLimit": "6"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-6h)", "description": "Exposure to ticagrelor during the first 6 hours after ticagrelor loading dose", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ng*h/mL", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2491", "lowerLimit": "189", "upperLimit": "5764"}, {"groupId": "OG001", "value": "5587", "lowerLimit": "2810", "upperLimit": "8546"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-6)", "description": "Exposure to ticagrelor metabolite during the first 6 hours after ticagrelor loading dose", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ng*h/mL", "timeFrame": "prior to the initial dose and 30min, 1h, 2h, 3h, 4h, 6h post dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "472", "lowerLimit": "0", "upperLimit": "1036"}, {"groupId": "OG001", "value": "1001", "lowerLimit": "643", "upperLimit": "1666"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "prior to the initial ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88.5", "lowerLimit": "82.9", "upperLimit": "93.5"}, {"groupId": "OG001", "value": "88.3", "lowerLimit": "81.5", "upperLimit": "94.0"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "30 minutes post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "83.2", "lowerLimit": "74.5", "upperLimit": "89.7"}, {"groupId": "OG001", "value": "73.9", "lowerLimit": "42.6", "upperLimit": "87.7"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "1 hour post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "70.2", "lowerLimit": "34.1", "upperLimit": "87.2"}, {"groupId": "OG001", "value": "42.0", "lowerLimit": "25.6", "upperLimit": "81.2"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "2 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52.1", "lowerLimit": "21.7", "upperLimit": "80.5"}, {"groupId": "OG001", "value": "26.2", "lowerLimit": "18.7", "upperLimit": "52.1"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "3 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37.8", "lowerLimit": "24.7", "upperLimit": "75.1"}, {"groupId": "OG001", "value": "26.0", "lowerLimit": "13.1", "upperLimit": "52.4"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "4 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.9", "lowerLimit": "19.1", "upperLimit": "64.1"}, {"groupId": "OG001", "value": "23.2", "lowerLimit": "14.3", "upperLimit": "43.4"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "6 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.9", "lowerLimit": "18.2", "upperLimit": "44.1"}, {"groupId": "OG001", "value": "19.7", "lowerLimit": "12.7", "upperLimit": "33.0"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Reactivity Index Assessed by VASP Assay", "description": "Platelet Reactivity Index (PRI) evaluated by VASP assay (cut-off value for high platelet reactivity: PRI \\>50%)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Reactivity Index (%)", "timeFrame": "12 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.5", "lowerLimit": "17.0", "upperLimit": "42.3"}, {"groupId": "OG001", "value": "15.6", "lowerLimit": "12.3", "upperLimit": "33.1"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "prior to the initial ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "85", "lowerLimit": "70", "upperLimit": "102"}, {"groupId": "OG001", "value": "77", "lowerLimit": "54", "upperLimit": "95"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "30 minutes post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86", "lowerLimit": "53", "upperLimit": "99"}, {"groupId": "OG001", "value": "48", "lowerLimit": "22", "upperLimit": "89"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "1 hour post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "59", "lowerLimit": "31", "upperLimit": "86"}, {"groupId": "OG001", "value": "23", "lowerLimit": "17", "upperLimit": "60"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "2 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31", "lowerLimit": "20", "upperLimit": "71"}, {"groupId": "OG001", "value": "23", "lowerLimit": "10", "upperLimit": "36"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "3 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27", "lowerLimit": "18", "upperLimit": "55"}, {"groupId": "OG001", "value": "17", "lowerLimit": "10", "upperLimit": "23"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "4 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29", "lowerLimit": "10", "upperLimit": "44"}, {"groupId": "OG001", "value": "13", "lowerLimit": "9", "upperLimit": "22"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "6 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19", "lowerLimit": "9", "upperLimit": "34"}, {"groupId": "OG001", "value": "11", "lowerLimit": "5", "upperLimit": "15"}]}]}]}, {"type": "SECONDARY", "title": "Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry", "description": "Platelet reactivity assessed by Multiple Electrode Aggregometry (cut-off value for high platelet reactivity: AUC \\>46 Platelet Arbitrary Aggregation Units)", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Platelet Arbitrary Aggregation Units", "timeFrame": "12 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19", "lowerLimit": "10", "upperLimit": "27"}, {"groupId": "OG001", "value": "11", "lowerLimit": "7", "upperLimit": "16"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "prior to the initial ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "232.5", "lowerLimit": "197.0", "upperLimit": "270.0"}, {"groupId": "OG001", "value": "238.5", "lowerLimit": "194.0", "upperLimit": "267.0"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "30 minutes post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "268.5", "lowerLimit": "202.0", "upperLimit": "299.0"}, {"groupId": "OG001", "value": "210.5", "lowerLimit": "118.0", "upperLimit": "266.0"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "1 hour post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "206.5", "lowerLimit": "88.0", "upperLimit": "266.0"}, {"groupId": "OG001", "value": "117.0", "lowerLimit": "10.0", "upperLimit": "233.0"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "2 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "137.0", "lowerLimit": "27.0", "upperLimit": "251.0"}, {"groupId": "OG001", "value": "44.0", "lowerLimit": "7.0", "upperLimit": "119.0"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "3 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "113.0", "lowerLimit": "31.0", "upperLimit": "221.0"}, {"groupId": "OG001", "value": "15.0", "lowerLimit": "4.0", "upperLimit": "52.0"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "4 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.5", "lowerLimit": "8.0", "upperLimit": "165.0"}, {"groupId": "OG001", "value": "9.0", "lowerLimit": "4.0", "upperLimit": "72.0"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "6 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44.5", "lowerLimit": "6.0", "upperLimit": "171.0"}, {"groupId": "OG001", "value": "8.0", "lowerLimit": "3.0", "upperLimit": "21.0"}]}]}]}, {"type": "SECONDARY", "title": "P2Y12 Reaction Units Assessed by VerifyNow", "description": "P2Y12 Reaction Units (PRU) Assessed by VerifyNow (cut-off value for high platelet reactivity: PRU \\>208)", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "P2Y12 Reaction Units", "timeFrame": "12 hours post ticagrelor dose", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.0", "lowerLimit": "4.0", "upperLimit": "116.0"}, {"groupId": "OG001", "value": "7.5", "lowerLimit": "3.0", "upperLimit": "48.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VASP", "description": "Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VASP", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Patients With HPR", "timeFrame": "2 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "29"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With MEA", "description": "Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With MEA", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Patients With HPR", "timeFrame": "2 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "14"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VerifyNow", "description": "Percentage of Patients With High Platelet Reactivity (HPR) After the Loading Dose of Ticagrelor Assessed With VerifyNow", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Patients With HPR", "timeFrame": "2 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "19"}]}]}]}, {"type": "SECONDARY", "title": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VASP", "description": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VASP", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "lowerLimit": "1.0", "upperLimit": "6.0"}, {"groupId": "OG001", "value": "1", "lowerLimit": "0.5", "upperLimit": "3"}]}]}]}, {"type": "SECONDARY", "title": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With MEA", "description": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With MEA", "populationDescription": "According to the study protocol multiple electrode aggregometry pharmacodynamic evaluation was performed in all patients except for those treated with glycoprotein (GP) IIb/IIIa receptor inhibitors.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "lowerLimit": "1.0", "upperLimit": "4.0"}, {"groupId": "OG001", "value": "1.0", "lowerLimit": "0.5", "upperLimit": "2.0"}]}]}]}, {"type": "SECONDARY", "title": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VerifyNow", "description": "Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity (HPR) Evaluated With VerifyNow", "populationDescription": "In line with the study protocol, VerifyNow pharmacodynamic evaluation involved \\>30% of the overall study population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}, {"id": "OG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "lowerLimit": "0", "upperLimit": "3.0"}, {"groupId": "OG001", "value": "0.5", "lowerLimit": "0", "upperLimit": "1.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "7 days", "eventGroups": [{"id": "EG000", "title": "Morphine", "description": "morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nMorphine: IV bolus injection\n\nTicagrelor: 180 mg loading dose", "seriousNumAffected": 1, "seriousNumAtRisk": 35, "otherNumAffected": 5, "otherNumAtRisk": 35}, {"id": "EG001", "title": "Placebo", "description": "sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor\n\nPlacebo: IV bolus injection\n\nTicagrelor: 180 mg loading dose", "seriousNumAffected": 2, "seriousNumAtRisk": 35, "otherNumAffected": 7, "otherNumAtRisk": 35}], "seriousEvents": [{"term": "Stent thrombosis", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 35}]}, {"term": "Pulmonary oedema", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 35}]}], "otherEvents": [{"term": "TIMI minor bleeding", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 35}]}, {"term": "TIMI minimal bleeding", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 35}]}, {"term": "Bradyarrhythmic event", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 35}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 35}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 35}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Prof. Jacek Kubica", "organization": "Collegium Medicum, Nicolaus Copernicus University", "email": "jkubica@cm.umk.pl", "phone": "+485854023"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000072657", "term": "ST Elevation Myocardial Infarction"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}], "browseLeaves": [{"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M1072", "name": "ST Elevation Myocardial Infarction", "asFound": "ST-segment Elevation Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000009020", "term": "Morphine"}, {"id": "D000077486", "term": "Ticagrelor"}], "ancestors": [{"id": "D000000701", "term": "Analgesics, Opioid"}, {"id": "D000009294", "term": "Narcotics"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000058921", "term": "Purinergic P2Y Receptor Antagonists"}, {"id": "D000058919", "term": "Purinergic P2 Receptor Antagonists"}, {"id": "D000058914", "term": "Purinergic Antagonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11982", "name": "Morphine", "asFound": "400", "relevance": "HIGH"}, {"id": "M1812", "name": "Ticagrelor", "asFound": "Immediate", "relevance": "HIGH"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M4033", "name": "Analgesics, Opioid", "relevance": "LOW"}, {"id": "M12245", "name": "Narcotics", "relevance": "LOW"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M29294", "name": "Purinergic P2Y Receptor Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}]}}, "hasResults": true}